Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Zenas BioPharma, Inc. ( (ZBIO) ) is now available.
On February 10, 2026, Zenas BioPharma’s Board of Directors approved an Amended and Restated Short-Term Incentive Plan, effective January 1, 2026, establishing an annual discretionary cash bonus program for eligible employees based on company performance and individual goal achievement. The plan centralizes broad discretion with the Board, its committees, and senior leadership over eligibility, award determination, payment timing, and interpretation, while subjecting payouts to recoupment policies and allowing the company to amend or discontinue the program, underscoring a flexible but tightly controlled approach to incentive compensation and risk management.
The most recent analyst rating on (ZBIO) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
Spark’s Take on ZBIO Stock
According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.
The score is held back primarily by substantial ongoing losses and cash burn, alongside a bearish technical setup. Offsetting factors include a low-leverage balance sheet and strong, positive Phase 3/Phase 2 clinical readouts with planned 2026 regulatory filings, which meaningfully improve the strategic outlook but still leave near-term financial sustainability and execution as key constraints.
To see Spark’s full report on ZBIO stock, click here.
More about Zenas BioPharma, Inc.
Zenas BioPharma, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing therapies through its own operations and subsidiaries. The company employs regular full- and part-time staff whose compensation structure includes performance-based incentive components aligned with corporate and individual goals.
Average Trading Volume: 735,096
Technical Sentiment Signal: Buy
Current Market Cap: $1.25B
Find detailed analytics on ZBIO stock on TipRanks’ Stock Analysis page.